Uri Galili
#129,033
Most Influential Person Now
Researcher
Uri Galili's AcademicInfluence.com Rankings
Uri Galilicomputer-science Degrees
Computer Science
#5582
World Rank
#5896
Historical Rank
Machine Learning
#1538
World Rank
#1560
Historical Rank
Artificial Intelligence
#1770
World Rank
#1802
Historical Rank
Database
#2728
World Rank
#2852
Historical Rank

Download Badge
Computer Science
Uri Galili's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Uri Galili Influential?
(Suggest an Edit or Addition)Uri Galili's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. (1988) (876)
- A unique natural human IgG antibody with anti-alpha-galactosyl specificity (1984) (653)
- Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. (1993) (627)
- Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora (1988) (501)
- Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. (1987) (495)
- Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues (1985) (381)
- The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance (2008) (320)
- Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. (1991) (300)
- On the Role of Cell Surface Carbohydrates and their Binding Proteins (lectins) in Tumor Metastasis (2004) (278)
- The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy (2005) (272)
- One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. (1993) (222)
- The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies (1987) (211)
- The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation. (2001) (187)
- Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits (2013) (174)
- The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. (2005) (169)
- The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. (1974) (159)
- Immunogenic Gal alpha 1----3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. (1989) (155)
- Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. (2000) (152)
- Reversal of diabetes in non‐immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection (2004) (134)
- The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. (2008) (128)
- Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in anti-Gal response during chronic rejection. (1997) (125)
- A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. (1998) (125)
- Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of alpha-galactosidase-treated porcine cartilage. (1998) (121)
- Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody (2004) (116)
- Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. (1992) (115)
- Distribution of Gal.alpha.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay (1990) (112)
- Molecular mimicry in the recognition of glycosphingolipids by Galα3Galβ4GlcNAcβ-binding Clostridium difficile toxin A, human natural anti α-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor (1996) (109)
- Replacement of Human Anterior Cruciate Ligaments with Pig Ligaments: A Model for Anti-Non-Gal Antibody Response in Long-Term Xenotransplantation (2007) (104)
- Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. (1999) (103)
- Lectin-induced apoptosis of tumour cells. (1993) (103)
- Defining the minimal size of catalytically active primate alpha 1,3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme. (1994) (101)
- Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation. (1998) (96)
- Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. (1997) (93)
- The effect of radiation therapy on lymphocyte subpopulations in cancer patients (1976) (93)
- Immunogenicity of Influenza Virus Vaccine Is Increased by Anti-Gal-Mediated Targeting to Antigen-Presenting Cells (2007) (92)
- Adult and neonatal anti‐Gal response in knock‐out mice for α1,3galactosyltransferase (1998) (90)
- Changes in cell surface glycosylation in alpha1,3-galactosyltransferase knockout and alpha1,2-fucosyltransferase transgenic mice. (1997) (86)
- Identification of erythrocyte Gal alpha 1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13. (1987) (85)
- Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. (2004) (84)
- The natural anti‐α‐galactosyl IgG on human normal senescent red blood cells (1986) (84)
- Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. (1997) (82)
- Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions (1995) (80)
- Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells. (1983) (80)
- Increased Immunogenicity of Human Immunodeficiency Virus gp120 Engineered To Express Galα1-3Galβ1-4GlcNAc-R Epitopes (2006) (78)
- Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction. (1986) (77)
- Intratumoral Injection of α-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines (2007) (71)
- Anterior cruciate ligament reconstruction with a porcine xenograft: a serologic, histologic, and biomechanical study in primates. (2007) (70)
- Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. (2009) (70)
- Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection. (1995) (68)
- Rapid Recruitment and Activation of Macrophages by Anti-Gal/α-Gal Liposome Interaction Accelerates Wound Healing (2011) (66)
- Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. (1993) (66)
- Differential expression of alpha-GAL epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on pig and mouse organs. (2000) (63)
- Human anti-Gal heavy chain genes. Preferential use of VH3 and the presence of somatic mutations. (1995) (60)
- Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. (1996) (59)
- Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. (1996) (59)
- Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells. (1996) (59)
- Xenotransplantation and ABO incompatible transplantation: the similarities they share. (2006) (56)
- ABNORMAL EXPRESSION OF α-GALACTOSYL EPITOPES IN MAN A Trigger for Autoimmune Processes? (1989) (55)
- Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model. (1994) (55)
- The formation of stable E-rosettes by human T lymphocytes activated in mixed lymphocyte reactions. (1976) (51)
- Activated T cells in the synovial fluid of arthritic patients: characterization and comparison with in vitro activated human and murine T cells in cooperation with monocytes in cytotoxicity. (1979) (51)
- Discovery of the natural anti‐Gal antibody and its past and future relevance to medicine (2013) (50)
- Evolution in primates by "Catastrophic-selection" interplay between enveloped virus epidemics, mutated genes of enzymes synthesizing carbohydrate antigens, and natural anti-carbohydrate antibodies. (2019) (50)
- Accelerated healing of skin burns by anti-Gal/alpha-gal liposomes interaction. (2010) (49)
- Separation and characteristics of tumor-infiltrating lymphocytes in man. (1980) (49)
- Synthesis of α-Galactosyl Epitopes by Recombinant α1,3Galactosyltransferase for Opsonization of Human Tumor Cell Vaccines by Anti-Galactose (1996) (48)
- Erythrocyte membrane alterations in beta-thalassaemia. (1985) (48)
- Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen (2003) (48)
- Subpopulations of human thymus cells differing in their capacity to form stable E-rosettes and in their immunologic reactivity. (1975) (47)
- Significance of the Evolutionary α1,3-Galactosyltransferase (GGTA1) Gene Inactivation in Preventing Extinction of Apes and Old World Monkeys (2014) (46)
- Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates (1995) (45)
- Natural species-restricted attachment of human and murine T lymphocytes to various cells. (1978) (45)
- Metabolic and ultrastructural aspects of the in vitro lysis of chronic lymphocytic leukemia cells by glucocorticoids. (1982) (44)
- Age-associated changes in subpopulations of human lymphocytes. (1977) (43)
- α1,3Galactosyltransferase knockout pigs produce the natural anti‐Gal antibody and simulate the evolutionary appearance of this antibody in primates (2013) (42)
- The natural anti-Gal antibody, the B-like antigen, and human red cell aging. (1988) (42)
- Variations in activity of the human natural anti-Gal antibody in young and elderly populations. (1995) (42)
- Induced Anti-Non Gal Antibodies in Human Xenograft Recipients (2012) (42)
- The natural anti-Gal antibody. (1999) (39)
- Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. (2010) (37)
- Interaction of Baboon Anti-α-Galactosyl Antibody with Pig Tissues (1999) (36)
- Human T lymphocytes become glucocorticoid-sensitive upon immune activation. (1980) (36)
- Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer (2004) (34)
- Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. (2005) (34)
- Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(alpha)1-2-galactose after alpha1,2-fucosyltransferase cDNA transfection. (1997) (33)
- Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity (2009) (33)
- Elimination of anti-Gal B cells by alpha-Gal ricin1. (2002) (33)
- Anti-gal A/B, a novel anti-blood group antibody identified in recipients of abo-incompatible kidney allografts1 (2002) (33)
- Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type I activation. (1998) (33)
- Genes coding evolutionary novel anti-carbohydrate antibodies: studies on anti-Gal production in alpha 1,3galactosyltransferase knock out mice. (2000) (32)
- Accelerated Porcine Wound Healing after Treatment with &agr;-Gal Nanoparticles (2012) (32)
- Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma (1980) (32)
- Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. (2006) (32)
- Comparison of serum anti-band 3 and anti-Gal antibody binding to density-separated human red blood cells. (1991) (31)
- Molecular mimicry in the recognition of glycosphingolipids by Gal alpha 3 Gal beta 4 GlcNAc beta-binding Clostridium difficile toxin A, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the ani (1996) (31)
- Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen, II: tolerance induction on memory B cells. (2003) (31)
- Mouse-heart grafts expressing an incompatible carbohydrate antigen. II. Transition from accommodation to tolerance (2004) (30)
- Distribution of Gal alpha 1----3Gal beta 1----4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay. (1990) (30)
- Activated T cells in the synovial fluid of arthritic patients. II. In vitro activation of the autologous blood lymphocytes. (1981) (29)
- High‐affinity anti‐Gal immunoglobulin G in chronic rejection of xenografts (1997) (29)
- Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris (2001) (28)
- Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: In vitro differentiation, growth patterns, and ultrastructural observations (1982) (28)
- In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1,3galactosyltransferase gene (2005) (28)
- Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes (2020) (27)
- Human prothymocytes. Membrane properties, differentiation patterns, glucocorticoid sensitivity, and ultrastructural features (1980) (27)
- Synthesis of α-gal epitopes on influenza virus vaccines, by recombinant α1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody (1997) (27)
- Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics? (2016) (27)
- Evolution of α1,3Galactosyltransferase and of the α-Gal Epitope (1999) (26)
- Glucocorticoid induced cytolysis of human normal and malignant lymphocytes. (1983) (26)
- Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer (2015) (26)
- Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. (1995) (25)
- Triple immunosuppression reduces mononuclear cell infiltration and prolongs graft life in pig-to-newborn baboon cardiac xenotransplantation. (1998) (25)
- A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. (1996) (25)
- Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients1 (2002) (23)
- Specific stimulation of Graves' disease thyrocytes by the natural anti-Gal antibody from normal and autologous serum. (1994) (23)
- EA Rosette Formation: a Simple Means to Increase Sensitivity of the Antiglobulin Test in Patients with Anti Red Cell Antibodies (1981) (23)
- Avoiding detrimental human immune response against Mammalian extracellular matrix implants. (2015) (23)
- Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay (2006) (23)
- Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections (2020) (23)
- Cancer immunotherapy by intratumoral injection of α-gal glycolipids. (2012) (23)
- Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. (2003) (23)
- Control of metastatic properties of BL6 melanoma cells by H-2Kb gene: immunological and nonimmunological mechanisms (1993) (22)
- Lymphocyte subpopulations in chronic active hepatitis: increase in lymphocytes forming stable E-rosettes. (1975) (22)
- Understanding the Induced Antibody Response (2001) (22)
- The in vitro sensitivity of leukemic and normal leukocytes to hydrocortisone induced cytolysis. (1980) (22)
- Significance of anti-Gal IgG in chronic xenograft rejection. (1999) (22)
- The natural anti-Gal antibody: evolution and autoimmunity in man. (1991) (21)
- Analysis of the peanut agglutinin-binding site as a differentiation marker of normal and malignant human lymphoid cells. (1981) (21)
- Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. (1996) (21)
- Expression of α-gal epitopes on HeLa cells transduced with adenovirus containing α1,3galactosyltransferase cDNA (2002) (21)
- Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen. (2003) (21)
- Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells. (1993) (20)
- Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope. (1999) (20)
- Anti-αgalactosyl (Anti-Gal) Antibody Damage Beyond Hyperacute Rejection (1997) (20)
- α-Galactosyl (Galα1-3Galβ1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate α1,3galactosyltransferase expressed in E.coli (1995) (18)
- Topical α‐gal nanoparticles accelerate diabetic wound healing (2020) (17)
- Cloning of anti-Gal Fabs from combinatorial phage display libraries: structural analysis and comparison of Fab expression in pComb3H and pComb8 phage. (1997) (17)
- Use of the enzyme-linked immunoadsorbent assay to monitor the purification of glycosphingolipid antigens by high-performance liquid chromatography. (1987) (17)
- alpha-galactosyl epitopes on glycoproteins of porcine renal extracellular matrix. (2000) (16)
- Acceleration of Wound Healing by α-gal Nanoparticles Interacting with the Natural Anti-Gal Antibody (2015) (16)
- a-GALACTOSYL EPITOPE-MEDIATED ACTIVATION OF PORCINE AORTIC ENDOTHELIAL CELLS (1998) (15)
- Human anti-Gal heavy chain genes (1995) (14)
- Interaction between anti-Gal and human tumor cells: a natural defense mechanism? (1989) (14)
- Human T lymphocyte receptors for sheep red blood cells and specific antigens: are they identical sites on the cell membrane? (1977) (14)
- α-Gal Nanoparticles in Wound and Burn Healing Acceleration. (2017) (14)
- Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene (2004) (13)
- Effects of dexamethasone on proliferation of autologous fibroblasts and on the immune profile in women undergoing pelvic surgery for infertility. (1983) (13)
- Loss of net negative surface charge during MLC stimulation of human T lymphocytes: correlation to "stable" E-rosette formation and natural attachment to normal and malignant target cells. (1979) (12)
- Preparation of Autologous Leukemia and Lymphoma Vaccines Expressing α-Gal Epitopes (2001) (12)
- A naturally occurring anti-alpha-galactosyl IgG recognizing senescent human red cells. (1985) (12)
- Abnormal expression of alpha-galactosyl epitopes in man. A trigger for autoimmune processes? (1989) (12)
- In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids (2010) (12)
- Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α-Gal Glycolipids that Induce Anti-Gal/α-Gal Epitope Interaction (2011) (12)
- α-Gal and Anti-Gal (1999) (12)
- Lymphocytes of Hodgkin's biopsies exhibit: stable E-rosette formation, natural attachment and glucocorticoid sensitivity, similar to immunoactivated T cells. (1980) (11)
- The natural anti-alpha-galactosyl IgG on human normal senescent red blood cells. (1986) (11)
- Activated T lymphocytes within human solid tumors (1979) (11)
- Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma (2016) (10)
- Cellular Dehydration and Immunoglobulin Binding in Senescent Neonatal Erythrocytes (1988) (10)
- Be13, a human T-leukemia cell line highly sensitive to dexamethasone-induced cytolysis. (1984) (10)
- Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. (1997) (10)
- Association between HLA determinants and complement receptors on human lymphocytes. (2008) (10)
- Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as “Achilles’ Heel” of Viruses Contributing to Anti-Viral Immune Protection (2020) (10)
- Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris. (2001) (10)
- Significance of α-Gal (Galα1-3Galβ1-4GlcNAc-R) Epitopes and α1, 3 Galactosyltransferase in Xenotransplantation (1999) (10)
- The two antibody specificities within human anti-blood group B antibodies. (1988) (10)
- Evidence that tilapia islets do not express α‐(1,3)gal: implications for islet xenotransplantation (2004) (9)
- Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies (2021) (9)
- Differential expression of α-Gal epitopes on pig and mouse organs (2000) (9)
- Antigenic differences between T and B lymphocytes in man. (1974) (9)
- Determination of ABO Blood Group Zygosity by an Antiglobulin Rosetting Technique and Cell‐Based Enzyme Immunoassay (1986) (9)
- Anti-Gal in Humans and Its Antigen the α-Gal Epitope (2018) (8)
- Studies on the formation of E-rosettes by human T lymphocytes and thymus cells. Effects of temperature, metabolic inhibitors and anti-T sera. (1975) (8)
- Identification of b cells with receptors for α-Gal epitopes (Galα 1-3Galβ1-4GlcNac-R) in xenograft recipients (2000) (7)
- Blood lymphocytes in infectious mononucleosis share the following characteristics with activated T cells: natural attachment, stable E rosetting and glucocorticoid sensitivity. (1980) (7)
- The natural anti-alpha-galactosyl IgG in seminal fluid. A simple means to determine damage to the blood-genital tract barrier in infertile males. (1992) (7)
- New World monkeys as a primate model for xenografts in the absence of anti-Gal. (1996) (7)
- *Induced Remodeling of Porcine Tendons to Human Anterior Cruciate Ligaments by α-GAL Epitope Removal and Partial Cross-Linking (2017) (7)
- Enhancement of autologous tumor vaccine immunogenicity by anti-Gal. (1999) (7)
- Interaction of baboon anti-alpha-galactosyl antibody with pig tissues. (1999) (7)
- Macrophages Recruitment and Activation by α-gal NanoparticlesAccelerate Regeneration and Can Improve Biomaterials Efficacy in TissueEngineering (2013) (7)
- Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes. (2001) (7)
- Graves' disease as a model for anti-Gal involvement in autoimmune diseases. (1999) (7)
- Antigen-Mediated, Macrophage-Stimulated, Accelerated Wound Healing Using &agr;-Gal Nanoparticles (2018) (7)
- Differential immune response to carbohydrate epitopes on allo- and xenografts: implications for accommodation. (2000) (6)
- Prothymocytes in postirradiation regenerating rat thymuses: a model for studying early stages in T cell differentiation. (1983) (6)
- Conversion of tumors into autologous vaccines by intratumoral injection of alpha-Gal glycolipids that induce anti-Gal/alpha-Gal epitope interaction (2014) (6)
- Intracellular protease activity in glucocorticoid-mediated thymolysis. (1982) (6)
- α-gal and anti-gal : α1,3-galactosyltransferase, α-gal epitopes, and the natural anti-gal antibody subcellular biochemistry (1999) (6)
- alpha-Gal epitopes on viral glycoproteins. (1999) (6)
- Evolution of the Galα1-3Galβ1-4GlcNAc-R Epitope in Mammals (1990) (6)
- α-Galactosyl antibody redistributes α-galactosyl at the surface of pig blood and endothelial cells (1999) (6)
- Human Anti-Gal and Anti-Non-Gal Immune Response to Porcine Tissue Implants (2015) (6)
- α-Gal Epitopes on Viral Glycoproteins (1999) (6)
- XX/XY lymphoid chimerism in a boy with fatal lymphohistiocytic proliferation. (1981) (5)
- Preventing anti-Gal response in xenograft recipients by an α-gal toxin (2001) (5)
- Anti-Gal and human red cell aging. (1989) (5)
- The nature of elicited xenoantibodies. (2001) (5)
- The α-Galactosyl Epitope (Galα1-3Ga1β1-4GIcNAc-R) and the Natural Anti-Gal Antibody (1997) (5)
- Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA. (2002) (5)
- The alpha-galactosyl epitope on human normal and autoimmune thyroid cells. (1991) (5)
- In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids (2013) (5)
- Near Complete Repair After Myocardial Infarction in Adult Mice by Altering the Inflammatory Response With Intramyocardial Injection of α-Gal Nanoparticles (2021) (5)
- Alpha-Galactosyl (Anti-Gal) Autoantibodies (1996) (4)
- Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. (2004) (4)
- In Situ “Humanization” of Porcine Bioprostheses: Demonstration of Tendon Bioprostheses Conversion into Human ACL and Possible Implications for Heart Valve Bioprostheses (2021) (4)
- Glucocorticoid-induced lysis of human leukemia cells. (1988) (4)
- The Rosetting Antiglobulin Test as a Means of Determining the D Zygosity of Human Red Cells (1984) (4)
- The alpha-galactosyl epitope on mammalian thyroid cells. (1991) (4)
- T cells interacting with the α-Gal epitope: studies in α1,3Galactosyltransferase knock-out mice (2000) (3)
- Topical α-Gal Nanoparticles Enhance Wound Healing in Radiated Skin (2021) (3)
- AGI-134, a fully synthetic α-Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles. (2016) (3)
- COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines (2021) (3)
- Differential expression of alpha-Gal epitopes on pig and mouse organs. (2000) (3)
- The natural attachment of thymocytes and activated T lymphocytes to normal and malignant cells: an interspecies study. (1980) (3)
- Specific attachment of T-lymphocytes from cancer patients to tumor cells. (1977) (3)
- Glucocorticoid-induced lysis of various subsets of acute lymphoblastic leukemia. (1983) (2)
- Regulation of the cytotoxic effect of human ‘normal killer cells’ on tumor cell lines by neuraminidase-treated T-lymphocytes (1978) (2)
- Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. (1998) (2)
- Preventing anti-Gal response in xenograft recipients by an alpha-Gal toxin. (2001) (2)
- Genes coding for anti-Gal in knock-out mice for the alpha1, 3Galactosyltransferase gene: analysis by hybridomas. (2000) (2)
- Human Anti-Gal IgG binds to the same receptor and mimics the effects of C. difficile in rat colon. (1996) (2)
- Excessive binding of the natural anti-alpha-galactosyl IgG to sickle red cells: enhancement of red cell destruction by a physiological process. (1985) (2)
- Phase I study to evaluate toxicity and feasibility of intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma. (2014) (2)
- Inhalation of α-gal/sialic acid liposomes: a novel approach for inhibition of influenza virus infection? (2016) (2)
- Alpha-galactosyl antibody redistributes alpha-galactosyl at the surface of pig blood and endothelial cells. (1999) (2)
- Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody. (2021) (2)
- Inhalation of α-Gal/Sialic Acid Liposomes for Decreasing Influenza Virus Infection (2018) (1)
- Elimination of anti-Gal B cells by &agr;-Gal ricin1 (2002) (1)
- Chapter 5 – Anti-Gal B Cells Are Tolerized by α-Gal Epitopes in the Absence of T Cell Help (2018) (1)
- Identification of B cells with receptors for alpha-Gal epitopes (Galalpha 1-3Galbeta1-4GlcNac-R) in xenograft recipients. (2000) (1)
- Chapter 10 – Cancer Immunotherapy by Anti-Gal-Mediated In Situ Conversion of Tumors Into Autologous Vaccines (2018) (1)
- A simple in vitro site directed mutagenesis of concatamerized cDNA by inverse polymerase chain reaction. (1992) (1)
- Anti-Gal and Anti-Non Gal Antibody Barriers in Xenotransplantation (2012) (1)
- Why Do We Produce Anti-Gal (2017) (1)
- Structure Function Studies of a New World Monkey (1999) (1)
- Anti-Gal Interaction With Trypanosoma , Leishmania , and Plasmodium Parasites (2018) (1)
- Anti-Gal Comprises Most of Anti-Blood Group B Antibodies (2018) (1)
- Preformed and elicited antibodies to pig antigens in nonhuman primates and humans (2001) (1)
- Acceleration of Wound and Burn Healing by Anti-Gal/α-Gal Nanoparticles Interaction (2018) (1)
- Topical Alpha-Gal Nanoparticles Enhances Wound Healing in Radiated Tissue (2019) (1)
- T cells interacting with the alpha-Gal epitope: studies in alpha1, 3Galactosyltransferase knock-out mice. (2000) (1)
- alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate alpha1,3galactosyltransferase expressed in E.coli. (1995) (1)
- 58: ACCELERATED PORCINE WOUND HEALING AFTER TREATMENT WITH ALPHA-GAL NANOPARTICLES (2011) (1)
- Anti-Gal and Autoimmunity (2018) (0)
- producing the natural anti-Gal antibody One percent of human circulating B lymphocytes are capable of (2011) (0)
- LONG-TERM FOLLOW-UP OF ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH AN IMMUNOCHEMICALY MODIFIED PORCINE XENOGRAFT (2009) (0)
- Autologous Tumor Vaccines Targeted In Vivo by Anti-GAL to Antigen Presenting Cells: A Phase I Study in Progress (2005) (0)
- Chapter 2 Why Do We Produce Anti-Gal Evolutionary Appearance of Anti-Gal in Old World Primates (2018) (0)
- Abstract 135: Anti α-Gal Nanoparticles Ameliorate Radiation-Induced Wound Healing Impairment (2019) (0)
- Paleo‐immunology of human anti‐carbohydrate antibodies preventing primate extinctions (2022) (0)
- Aberrant activity of alpha 1 3 galactosyltransferase and autoimmunity in graves disease (1990) (0)
- Chapter 9 – Anti-Gal-Mediated Amplification of Viral Vaccine Efficacy (2018) (0)
- ANTI‐CD40L TRANSIENTLY SUPPRESSES PRODUCTION OF ANTI‐GAL IgG BUT NOT IgM IN &agr;1,3GALACTOSYLTRANSFERASE KNOCK‐OUT MICE IMMUNIZED WITH PIG KIDNEY MEMBRANES.: Abstract# 143 (2000) (0)
- α-Gal: Antigen-Stimulated Macrophage-Directed Accelerated Wound Healing (2017) (0)
- A novel approach for inhibiting progression of flu virus infection at early stages of the disease by inhalation of α-Gal/SA liposomes (2015) (0)
- Xenograft-like destruction of tumors and their conversion into vaccines by intratumoral injection of {alpha}-gal glycolipids (2007) (0)
- Natural Xenoreactive Antibodies (2002) (0)
- Anti-Gal as Cancer Cell Destroying Antibody and as Antibiotics Targeted by α-Gal Bifunctional Molecules (2018) (0)
- 3.13 – Evolution and Clinical Significance of the α-Gal Epitope (2007) (0)
- Anti-Gal and Other Immune Barriers in Xenotransplantation (2018) (0)
- S10.5 Binding ofClostridium difficile toxin A to glycosphingolipids; identification of a novel binding-active carbohydrate sequence present in human tissue (1993) (0)
- Anti-Gal and Anti-non Gal Antibodies in Regeneration of Extracellular Matrix Bio-Implants (2018) (0)
- S2.15 Minimal size of active primateα1,3 galactosyltransferase (1993) (0)
- Significance of the Evolutionary α1,3-Galactosyltransferase (GGTA1) Gene Inactivation in Preventing Extinction of Apes and Old World Monkeys (2014) (0)
- Anti-Gal IgE Mediates Allergies to Red Meat (2018) (0)
- TOLERANCE INDUCTION TO ABO BLOOD GROUP ANTIGENS BY USING AUTOLOGOUS LYMPHOCYTES ENGINEERED TO EXPRESS THE COGNATE ANTIGEN: 1485 (2008) (0)
- Regeneration of Injured Spinal Cord and Peripheral Nerves by α-Gal Nanoparticles (2018) (0)
- Anti- (cid:97) -Galactosyl Immunoglobulin A (IgA), IgG, and IgM in Human Secretions† (1995) (0)
- on memory B cells by syngeneic lymphocytes expressing the antigen: II. Tolerance induction Tolerance induction to a mammalian blood group like carbohydrate antigen (2013) (0)
- Abstract: Improving Wound Healing Using α-gal: Antibody Stimulated Macrophage Directed Wound Healing (2016) (0)
- Chapter 14 – Post Infarction Regeneration of Ischemic Myocardium by Intramyocardial Injection of α-Gal Nanoparticles (2018) (0)
- Structure function studies of a New World monkey alpha 1,3galactosyltransferase. Analysis of alternative splicing and expression in baculovirus system. (1999) (0)
- A SIMPLE GENERAL METHOD FOR OPSONIZATION OF HUMAN AUTOLOGOUS TUMOR VACCINES BY THE NATURAL ANTI-GAL ANTIBODY (1994) (0)
- Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer (2015) (0)
- Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma (2014) (0)
- Proceedings: Delineation of distinct subpopulations of human thymus cells. (1975) (0)
- Xenograft Like Rejection of Tumor Lesions by Gene Therapy (2005) (0)
- α-Gal Nanoparticles Mediated Homing of Endogenous Stem Cells for Repair and Regeneration of External and Internal Injuries by Localized Complement Activation and Macrophage Recruitment (2022) (0)
- Compositions et procedes d'obtention de vaccins comprenant des epitopes d'alpha-galactosyl (1995) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Uri Galili?
Uri Galili is affiliated with the following schools: